Details

Autor(en) / Beteiligte

• Carr, Edward J
• Wu, Mary
• Harvey, Ruth
• Wall, Emma C
• Kelly, Gavin
• Hussain, Saira
• Howell, Michael
• Kassiotis, George
• Swanton, Charles
• Gandhi, Sonia
• Bauer, David LV
• Adenwalla, Sherna F
• Bird, Paul
• Holmes, Christopher
• Hull, Katherine L
• March, Daniel S
• Selvaskandan, Haresh
• Silva, Jorge J
• Tang, Julian W
• Hester, Joanna
• Issa, Fadi
• Barnardo, Martin
• Friend, Peter J
• Davenport, Andrew
• Goodlad, Catriona
• Gopalan, Vignesh
• Tangwonglert, Theerasak
• Stauss, Hans J
• Richter, Alex G
• Cunningham, Adam F
• Perez-Toledo, Marisol
• Banham, Gemma D
• Wall, Nadya
• Clarke, Candice L
• Prendecki, Maria
• Clayton, Bobbi
• Namjou, Sina
• Silva, Vanessa
• Poulten, Meghan
• Bawumia, Philip
• Miah, Murad
• Sade, Samuel
• Miranda, Mauro
• Taylor, Tom
• D'Angelo, Ilenia
• Cabrera Jarana, Mercedes
• Rahman, Mahbubur
• Abreu, Janet
• Sandhar, Sandeep
• Bailey, Neil
• Caidan, Simon
• Caulfield, Marie
• Adams, Lorin
• Kavanagh, Caitlin
• Warchal, Scott
• Sawyer, Chelsea
• Gavrielides, Mike
• Kandasamy, Jag
• Ambrose, Karen
• Strange, Amy
• Abiola, Titilayo
• O'Reilly, Nicola
• Hobson, Philip
• Agau-Doce, Ana
• Russell, Emma
• Riddell, Andrew
• Kjaer, Svend
• Borg, Annabel
• Roustan, Chloë
• Billany, Roseanne E
• Graham-Brown, Matthew PM
• Beckett, Joseph
• Bull, Katherine
• Shankar, Sushma
• Henderson, Scott
• Motallebzadeh, Reza
• Salama, Alan D
• Harper, Lorraine
• Mark, Patrick B
• McAdoo, Stephen
• Willicombe, Michelle
• Beale, Rupert

Titel

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

Ist Teil von

• The Lancet (British edition), 2021-09, Vol.398 (10305), p.1038-1041

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• [...]the subunit hepatitis B vaccine had to be re-formulated for this patient group to deliver a higher antigenic dose.3 There is uncertainty whether an mRNA or an adenoviral-vectored COVID-19 vaccine could provide clinical protection in this population or how long that protection lasts given the known waning of SARS-CoV-2 antibodies after natural infection.4 In the UK, most in-centre haemodialysis patients were vaccinated by their dialysis care team as part of the Joint Committee on Vaccination and Immunisation (JCVI) priority group 4,3 resulting in rapid delivery of doses to this at-risk population (appendix p 2). A similar pattern of improved responses in infection-experienced patients, in anti-S titres rather than neutralising antibody, has been reported for the single-dose adenoviral-vectored vaccine Ad26.CoV.2.13 We sought to compare neutralising antibody responses between seronaive haemodialysis patients and the healthy individuals we have already reported on as part of the Legacy study.11,12 As a control group, we selected Legacy participants who had never reported COVID-19 symptoms (therefore probably infection-naive and sero-naive) and had received two doses of either vaccine. [...]two doses of either vaccine consolidates antibody immunity in infection-experienced individuals. [...]AZD1222 alone in seronaive individuals induces suboptimal nAbT against all VOCs, including the delta variant that is dominant globally.